延长吉非替尼或厄洛替尼给药间隔时间治疗肺腺癌12例  

Extension of gefitinib or erlotinib administration interval in the treatment of 12 cases of lung adenocarcinoma

作　　者：康马飞[1] 李碧惠 董翠梅[1] 骆梅青[1] 李扬[1] 

机构地区：[1]桂林医学院附属医院肿瘤内科,广西桂林541001

出　　处：《中国现代医生》2016年第31期57-59,共3页China Modern Doctor

摘　　要：目的 分析延长吉非替尼或厄洛替尼给药间隔时间治疗肺腺癌的结果 ,为使用EGFR酪氨酸激酶抑制剂治疗肺癌提供新的思路。方法 2009年3月-2016年9月,对我院肿瘤内科12例在吉非替尼或厄洛替尼常规剂量治疗过程中因各种原因将剂量改为每2天或每3天口服1次的EGFR突变肺腺癌患者进行随访,记录患者延长给药间隔时间后疾病进展时间（TTP）。结果 延长给药间隔时间后,TTP最长者达40个月,最短为2个月。使用吉非替尼者8例中,TTP最长者达40个月,最短为2个月。使用厄洛替尼者4例中,TTP最长者达11个月,最短为2个月。改变用药频率后,疾病稳定时间较长的基本上均是EGFR基因19外显子突变的患者。结论 延长吉非替尼或厄洛替尼给药间隔时间治疗肺腺癌,特别是EGFR基因19外显子突变的肺腺癌可能是可行的。Objective To analyze the results of treatment of lung adenocarcinoma with extended administration interval of gefitinib or erlotinib and to provide a new idea for the treatment of lung cancer with EGFR tyrosine kinase inhibitor. Methods A total of 12 patients with lung adenocareinoma complicated with EGFR mutations who were receiving regu- lar dosage of gefitinib or erlotinib and changed the dosage to once every two or three days due to various reasons in the Department of Oncology in our hospital were followed up from March 2009 to September 2016. The time to disease pro- gression （TTP） was recorded for patients after extension of administration intervals. Results After extension of adminis- tration interval, the longest TTP was 40 months and the shortest was two months. Of the 8 patients who received gefi- tinib, the longest TTP was 40 months and the shortest was two months. Of the 4 patients who received erlotinib, the longest TTP was 11 months and the shortest was two months. After changing the frequency of drug use, patients with a longer disease-stabilizing time were found to have mutations in EGFR-19 exons. Conclusion It may be feasible to pro- long the interval of administration of gefitinib or erlotinib in the treatment of adenocarcinoma of the lung, especially the exon mutation of EGFR-19 in lung adenocarcinoma.

关 键 词：肺肿瘤 肺腺癌 吉非替尼 厄洛替尼 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]